Skip to main content

Market Overview

Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg

Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg
  • The European Medical Agency (EMA) is reportedly set to recommend Johnson & Johnson’s (NYSE: JNJ) coronavirus vaccine on March 11, according to Bloomberg.
  • The European Commission said deliveries of the J&J shot are expected to begin in early April, thus bolstering the supplies over the second and third quarters.
  • The EU inked a purchase deal with JNJ to supply doses for 200 million people, with an option for an additional 200 million. 
  • The EU official also said that the agency is in talks with Russian authorities on the Sputnik V vaccine and may receive data soon to begin a rolling review process.
  • The EMA is also carrying out a rolling review of the CureVac BV (NASDAQ: CVAC) and Novavax Inc (NASDAQ: NVAX) shots.
  • The European Commission has agreed to purchase 225 million CureVac shots and 100 million doses from Novavax.
  • On Wednesday, the FDA backed the JNJ’s single-shot COVID-19 vaccine, which protected from the infection after receiving the vaccine.
  • The FDA Adcom meeting to review JNJ’s shot is scheduled today.
  • Price Action: JNJ shares are up by 0.28% at $163.21, NVAX shares are down 1.4% at $218.4, and CVAC shares are up 1.5% at $94.36 in the premarket session on the last check Friday.

Related Articles (NVAX + JNJ)

View Comments and Join the Discussion!

Posted-In: Bloomberg COVID-19 VaccineBiotech News FDA Top Stories General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at